Strategies to Overcome Therapeutic Inertia in Type 2 Diabetes Mellitus: A Scoping Review

被引:12
|
作者
Wrzal, Paulina K. [1 ]
Bunko, Andrean [2 ]
Myageri, Varun [2 ]
Kukaswadia, Atif [2 ]
Neish, Calum S. [2 ]
Ivers, Noah M. [3 ,4 ]
机构
[1] Novo Nordisk Canada Inc, Med Affairs, 2476 Argentia Rd 101, Mississauga, ON L5N 6M1, Canada
[2] IQVIA, Real World Solut, Mississauga, ON, Canada
[3] Womens Coll Hosp, Dept Family Med, Toronto, ON, Canada
[4] Univ Toronto, Toronto, ON, Canada
关键词
barriers to care; scoping review; therapeutic inertia; type; 2; diabetes; CLINICAL-PRACTICE GUIDELINES; PRIMARY-CARE; INSULIN INITIATION; TREATMENT INTENSIFICATION; QUALITY IMPROVEMENT; GLYCEMIC CONTROL; CONTROLLED-TRIAL; MANAGEMENT; IMPACT; BARRIERS;
D O I
10.1016/j.jcjd.2020.08.109
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The objectives of this review were to: 1) examine recent strategies and component interventions used to overcome therapeutic inertia in type 2 diabetes mellitus (T2DM), 2) map strategies to the causes of therapeutic inertia they target and 3) identify causes of therapeutic inertia in T2DM that have not been targeted by recent strategies. A systematic search of the literature published from January 2014 to December 2019 was conducted to identify strategies targeting therapeutic inertia in T2DM, and key strategy characteristics were extracted and summarized. The search identified 46 articles, employing a total of 50 strategies aimed at overcoming therapeutic inertia. Strategies were composed of an average of 3.3 interventions (range, 1 to 10) aimed at an average of 3.6 causes (range, 1 to 9); most (78%) included a type of educational strategy. Most strategies targeted causes of inertia at the patient (38%) or health-care professional (26%) levels only and 8% targeted health-care-system-level causes, whereas 28% targeted causes at multiple levels. No strategies focused on patients' attitudes toward disease or lack of trust in health-care professionals; none addressed health-care professionals' concerns over costs or lack of information on side effects/fear of causing harm, or the lack of a health-care-system-level disease registry. Strategies to overcome therapeutic inertia in T2DM commonly employed multiple interventions, but novel strategies with interventions that simultaneously target multiple levels warrant further study. Although educational interventions are commonly used to address therapeutic inertia, future strategies may benefit from addressing a wider range of determinants of behaviour change to overcome therapeutic inertia. (c) 2020 The Author(s). Published on behalf of the Canadian Diabetes Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:273 / +
页数:22
相关论文
共 50 条
  • [21] Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review
    Khunti, Kamlesh
    Gomes, Marilia B.
    Pocock, Stuart
    Shestakova, Marina V.
    Pintat, Stephane
    Fenici, Peter
    Hammar, Niklas
    Medina, Jesus
    DIABETES OBESITY & METABOLISM, 2018, 20 (02): : 427 - 437
  • [22] Factors associated with therapeutic inertia in individuals with type 2 diabetes mellitus started on basal insulin
    Shabnam, Sharmin
    Gillies, Clare L.
    Davies, Melanie J.
    Dex, Terry
    Melson, Eka
    Khunti, Kamlesh
    Webb, David R.
    Zaccardi, Francesco
    Seidu, Samuel
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 203
  • [23] Type 2 diabetes mellitus-Its global prevalence and therapeutic strategies
    Jain, Shelesh
    Saraf, Swarnlata
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2010, 4 (01) : 48 - 56
  • [24] INJECTABLE THERAPY IN TYPE 2 DIABETES MELLITUS: STRATEGIES TO IMPROVE THERAPEUTIC ADHERENCE
    Gurova, Olga Y.
    Fadeev, Valentin V.
    Maloletkina, Ekaterina S.
    DIABETES MELLITUS, 2018, 21 (06): : 524 - 533
  • [25] RepaglinideA Review of its Therapeutic Use in Type 2 Diabetes Mellitus
    Christine R. Culy
    Blair Jarvis
    Drugs, 2001, 61 : 1625 - 1660
  • [26] MiglitolA Review of its Therapeutic Potential in Type 2 Diabetes Mellitus
    Lesley J. Scott
    Caroline M. Spencer
    Drugs, 2000, 59 : 521 - 549
  • [27] Repaglinide - A review of its therapeutic use in type 2 diabetes mellitus
    Culy, CR
    Jarvis, B
    DRUGS, 2001, 61 (11) : 1625 - 1660
  • [28] Miglitol - A review of its therapeutic potential in type 2 diabetes mellitus
    Scott, LJ
    Spencer, CM
    DRUGS, 2000, 59 (03) : 521 - 549
  • [29] Glimepiride in type 2 diabetes mellitus: A review of the worldwide therapeutic experience
    Massi-Benedetti, M
    CLINICAL THERAPEUTICS, 2003, 25 (03) : 799 - 816
  • [30] Evaluation of the use of therapeutic footwear in people with diabetes mellitus - a scoping review
    Jorgetto, Juliana Vallim
    Gamba, Monica Antar
    Kusahara, Denise Miyuki
    JOURNAL OF DIABETES AND METABOLIC DISORDERS, 2019, 18 (02) : 613 - 624